All articles by Raghavi Joshi
Raghavi Joshi
M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter
JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment.
M&As this week: Datinvest, Shanghai Pharmaceuticals, Sunrise Bright Investment
Canadian company Datinvest International (Datinvest) has signed an agreement to purchase all the outstanding shares and share capital issued by biopharmaceutical company Exxel Pharma.
Deals this week: Cipla, Takeda Pharmaceutical, Cadila Healthcare
Indian pharmaceutical company Cipla plans to issue non-convertible debentures or bonds through a public offering or a private placement to raise Rs20bn ($293.2m).
M&As this week: Eli Lilly, Fujifilm Holdings, Canopy Growth
US-based healthcare company Eli Lilly and Company has agreed to acquire AurKa Pharma Inc.
Deals this week: GlaxoSmithKline, Ligand, Catalent Pharma Solutions
GlaxoSmithKline Plc (GSK) has issued 1.25% international bonds due May 2026 in a public offering to raise €1bn ($1.19bn).
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
M&As this week: Strides Shasun, Takeda Pharmaceutical, Eli Lilly
Indian bio-pharmaceuticals developer Strides Shasun has signed an agreement with Apotex to merge with the latter’s Australian subsidiary, Apotex.
Deals this week: MannKind, XtalPi, Ascendia Pharmaceuticals
Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug, Afrezza.
Deals this week: IntelGenx, Oasmia Pharmaceutical, Karo Pharma
Canadian oral drug delivery company IntelGenx Technologies plans to issue 300 units priced at $10,000 a unit in a private placement to raise $3m in Canada and the US.
M&As this week: United Therapeutics, Par Formulations, Endo Ventures
United Therapeutics Corporation has agreed to acquire SteadyMed for $216m.
Deals this week: CTD Holdings, Peptron, Hemispherx Biopharma
US-based biotechnology company CTD Holdings has completed issuing 20,000 units of series B convertible preferred stock for the development of its lead drug candidate Trappsol Cyclo.